Weight gain after stopping Eli Lilly’s new obesity treatment should help, not hurt the stock

Health, Fitness & Food

David Ricks, CEO, Eli Lilly
Scott Mlyn | CNBC

Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell.

Products You May Like

Articles You May Like

Spinach Feta Frittata
I Tried the Viral 3-2-8 Workout Plan For 30 Days — Now, I Get the Hype
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
French Onion Chicken Soup

Leave a Reply

Your email address will not be published. Required fields are marked *